Table 2.

Survey completion rates by demographic and clinical subgroups (percentage of all patients who completed at least one PROMIS survey).

Breast			Prostate
Subpopulation (total pts)	% of patients with survey	Median no. outpatient encounters	Subpopulation (total pts)	% of patients with survey	Median no. outpatient encounters
First line of treatment			First line of treatment
Surgery (2371)	29.5	9	Surgery (1796)	32.1	7
Surgery + Radiotherapy (1175)	29.3	10	Active surveillance (478)	49.8***	8
Systemic (223)	50.7***	16	Radiation (968)	19.6***	8
Surg + Rad + Systemic (4598)	37.8***	11	Hormone (1171)	31.2	9
Radiotherapy + Systemic (78)	34.6	14	Chemo (176)	39.8	18
Surgery + Systemic (2828)	41.2***	12	Other/Unknown (4347)	15.6***	7
Other/Unknown (212)	52.8***	8
Age			Age
<45 (2592)	36.8	10	<55 (780)	26.0	5
45–60 (4832)	36.9	11	55–75 (6113)	25.8	7
60–75 (3275)	37.0	11	>75 (2043)	16.5***	9
>75 (786)	31.8	10
Race			Race
White (7451)	33.8%	10	White (6415)	24.4	7
Black (403)	21.8***	11	Black (508)	13.4***	9
Hispanic (867)	42.7***	13	Hispanic (384)	24.2	7
Asian (2380)	45.4***	12	Asian (940)	29.0*	9
Other/Unknown (384)	37.5	10	Other/Unknown (689)	17.4***	5
Insurance status			Insurance status
Private (7660)	37.5	10	Private (2167)	28.1	5
Public (3212)	38.0	12	Public (6004)	23.1***	8
None/Unknown (613)	17.0***	10	None/Unknown (765)	16.2***	7
Stage at diagnosis			Stage at diagnosis
0 (1901)	28.5	9	1 (941)	33.9	8
1 (4108)	37.5***	10	2 (3193)	26.3***	8
2 (3222)	36.3***	11	3 (649)	36.5	7
3 (999)	37.6***	13	4 (452)	35.2	8
4 (340)	36.8*	10	Unknown (3701)	15.2***	7
Unknown (915)	48.6***	15

Bolded cells are significant based on a corrected pairwise T test relative to the reference category within that time bin (first listed group)

^*p <0.05 *,

^**p<0.01,

^***p<0.001